When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
A new study has refreshed decades-old statistical models for Parkinson’s disease, and in the process discovered that almost 1 million Americans will have the disease in 2020—more than…
According to patient recorded outcomes, the IN-Motion151 study met its co-primary endpoint of progression-free survival (PFS). Lead author Bernard Escudier, MD, of the Institut Gustave Roussy in Villejuif, France,…
Alexandra Golby, MD, principal investigator and professor of Neurosurgery and Radiology at Brigham and Women’s Hospital, discusses new imaging methods meant to reduce the complications of planning and…
ER visits related to food allergy in infants and toddlers 0 to 4 years of age have risen in recent years. In this video, Vivian Hernandez-Trujillo, MD discusses…
In a poster presentation at ASCO 2018, authors shared data from a recent study which suggest that testing and modulating the composition of the gut microbiome can have…
In the largest prospective study of angiogenesis in metastatic renal cell carcinoma (mRCC) patients to date, an Italian study yielded data that suggests sorafenib had no meaningful impact…
